CAMBRIDGE, Mass. — Takeda Pharmaceutical's cancer drug unit has started a late-stage clinical trial of a drug for treating a rare form of lymphoma, the company said.
The unit, Millennium, announced the start of a phase-3 trial to evaluate MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma, an aggressive non-Hodgkin's lymphoma.
"There is a significant unmet need for patients suffering from PTCL," Millennium chief medical officer Karen Ferrante said. "MLN8237 is being explored across a broad range of hematological malignancies and solid tumors. The initiation of this trial represents another major achievement in advancing the Millennium pipeline."